希少フラクションの臨床開発
Clinical development for rare fraction cancer

ファイザー株式会社 クリニカルリサーチ統括部 オンコロジー領域部
　　廣橋 朋子
　　Tomoko Hirohashi, PhD
　　Director, Clinical research, Oncology, Pfizer Japan

杉田 潤子（薬事部門）
Agenda

• Background
• Successful factors to enhance drug development for a rare fraction cancer
• Drug development plan in Japan for rare fraction of cancer
• Summary
Precision medicine for rare fraction cancer

Driver geneに対する分子標的治療薬の高い有効性

Difficult to initiate clinical study for rare fraction cancer

Points to be considered to pursue clinical development for rare fraction cancer

**Negative**

- Unclear regulatory path
- CoDx Development
- Limited indication (LCP)
- Large scale screening, long term enrollment
- Study Cost (inc. Human resources)
- EAP Cost

**Positive**

- High medical needs For the patients
- Expected large effect size
- Translation is good from animal to human
Rare fraction cancer

Lung Adenocarcinoma

- KRAS: 5%
- EGFR: 2~3%
- ALK: 1~2%
- Other?:
  - ROS
  - MET
  - NRAS
  - BRAF
  - MEK
  - PIK3CA
  - ERBB2

Pfizer Confidential
General Basket Trial (In case of G-FIH study)

Dose escalation

- Expansion A Mutation A (ALK)
  - Expansion B Mutation B (ROS1)
    - Expansion C Mutation C (MET)
      - Expansion D Mutation D

- US NDA
- AA
- FULL
Rare Fraction Cancer

The 3rd Party Sponsored (Asia only)

1~2%

5%

FULL PFE Sponsored (in the world)

The 3rd Party Sponsored:
Investigator initiated clinical trial (IICT) or External funding

2~3%

Under discussion Mixed Model?
Successful factors

• Focused on of a particular compound (anchor drug) or in a particular area (home ground)
• Efficient drug development strategy was available
• Flexible concept drug approval is existed (Pink sheet)
Efficient drug development strategy

The same compound

NSCLC ALK ~5%

ORR

CoDx for ALK

NSCLC ROS1 ~1~2%

ORR

CoDx for ROS1

NSCLC MET ~2~3%

ORR

CoDx for MET

- Large effect size is expected from preclinical data (all targets are "driver gene", KEY factor)
- ORR can be a primary endpoint
- Basket trial is easily available
- NGS will resolve the issue of multiple CoDx
Efficient drug development strategy

The same compound

<table>
<thead>
<tr>
<th>NSCLC ALK</th>
<th>NSCLC ROS1</th>
<th>NSCLC MET</th>
</tr>
</thead>
<tbody>
<tr>
<td>~5%</td>
<td><del>1</del>2%</td>
<td><del>2</del>3%</td>
</tr>
</tbody>
</table>

ORR

• No randomized trials for each indication are required BEFORE approval

For while 20% if a population of the patients with a common tumor types may continue to represent a relatively large patient group such that it is realistically possible to conduct “transitional” regulatory agency-mandated randomized trial (M. Maurie et.al. Oncology 2016;91:299-301)
Efficient drug development strategy

The same compound

- NSCLC ALK ~5%
- NSCLC ROS1 ~1~2%
- NSCLC MET ~2~3%

ORR (AA) → ORR (FULL) → ORR (FULL ?)

Randomized trial G-P3 was required for full approval

• No randomized trials for each indication are required from 2\textsuperscript{nd} indication
Executive Summary
FDA’s top cancer drug reviewer has taken to the podium to paint a picture of the next phase in cancer drug development, which includes new business models, a return to single-arm trials and a new emphasis on safety.

Richard Pazdur: FDA Office of Hematology and Oncology Products Director
Flexible drug approval concept in the US

...So profound that FDA’s primary advocate for randomized trials in oncology now acknowledges that randomized trials may be unnecessary, if not impossible, given the dramatic response rates shown by some of these targeted agents.

前例のない効果が示された場合は、必ずしもP3が必要であるとは限らない。
(特に希少の場合)
Flexible drug approval concept in the US

• Pazdur explained that many cancer patients enroll in randomized trials to cross over to the experimental drug at the time of disease progression. That suggests a “loss of equipoise and clearly the trial should not have been done.”

• “Single-arm trials do not give us comparative safety data. They give us a snapshot in time of the safety of a particular population or adverse events that occur. But one doesn’t know whether these are associated with the drug, one doesn’t know whether they are associated with the underlying disease,” he explained.

比較試験はむしろSafety評価として重要となる
→ 最初のIndication（肺がん）でP3が実施され安全性が確認されていていれば，同一癌腫のMutation違いの場合はP3の比較試験は必要がない
Flexible drug approval concept in the US

...FDA could approve a drug indicated not for a particular type of cancer but for inhibiting a particular molecular pathway. “There is nothing in the legislation that would prohibit us from approving a drug for inhibiting pathway X or inhibiting pathway Y without any reference to a known established disease here. So that is open, we do have that degree of flexibility.”

臓器ごとの承認ではなく標的分子別の適応で承認する可能性もある。
ALCOMAでの適応取得を支持する考え方？
• If successful factors are exited, drug development for rare fraction cancer can be enhanced and activated

How about Japan?
How to establish drug development plan in Japan for rare fraction cancer
Conduct/Participate into basket trial (G-FIH) vs Conduct local/regional phase 2 study
Japan participation into basket Trial (G-FIH study)

Dose escalation

Expansion A
Mutation A
Japan join

Expansion B
Mutation B
Japan join

Expansion C
Mutation C
Japan join

Expansion D
Mutation D
Japan join

USNDA J-NDA

USNDA J-NDA

USNDA J-NDA

USNDA J-NDA
Points to be considered

• How to set enough sample size of J-pts for each cohort for JNDA?
  – Need to show consistency between non-Japanese and Japanese on the primary endpoint?
  – Additional clinical study is required?

• From Japan regulatory perspective, Phase 1 is considered as “for safety”
  – Endpoint can be acceptable from Japan regulatory authority?

• Can we meet CoDx development (approval and launch)?
Flexible action in the US for CoDx approval

POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitment:

3036-1 Commitment to support the availability, through the use of clinical trial data, of an in-vitro diagnostic device that is essential to the safe and effective use of crizotinib for patients with ROS1 rearrangements in metastatic non-small cell lung cancer (mNSCLC) tumor specimens.

The timetable you submitted on Mar 02, 2016, states that you will support the submission of a Premarket Approval (PMA) Application to FDA/CDRH according to the following schedule:

- Final Report Submission: December 2017

http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/202570Orig1s016ltr.pdf
Conduct local/regional phase 2 study (Concept)

In case of rare fraction cancer, “N-of-1 Trial” for rare disease can be applicable if;
- a primary endpoint can be ORR
- indication will be obtained regardless of line

If same approach is used in single arm study, robust data packaged (compared with standard of care) can be obtained.
**Single arm study having a SOC data at maximum**

<table>
<thead>
<tr>
<th>1st Regimen</th>
<th>2nd Regimen</th>
<th>3rd Regimen</th>
<th>4th Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1st regimen</th>
<th>2nd regimen</th>
<th>3rd regimen</th>
<th>4th regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOC</td>
<td>50%</td>
<td>40%</td>
<td>30%</td>
</tr>
<tr>
<td>治験薬</td>
<td>70%</td>
<td>60%</td>
<td>70%</td>
</tr>
</tbody>
</table>

Pfizer Confidential
Points to be considered

• The regulatory success rate might be higher than joining basket trial
  – Robust data packages can be obtained such, including a certain level of SOC data
• Drug lag must be existed
• Difficult to get endorsement for an additional regional study

(Mitigation plan)
  – Then the 3rd party collaboration (IICT or external funding) will be effectively used
  – If SOC data can be obtained from real world data (both safety and efficacy), the sample size can be minimized
Summary

• In global perspective, drug development for rare fraction cancer can be enhanced and activated, if successful factors are exited
  – Efficient drug development strategy is available
  – Flexible concept drug approval is existed (Pink sheet)

• On the other hand, still some difficulties are existed in Japan
  – Less experiences of the 3rd party collaboration
  – Regulatory path for clinical development of rare fraction cancer has not been established yet

• Japan requires a regulatory scheme for drug development/approval for rare fraction cancer
  – Flexibility for both drug and CoDx approvals
  – Additional regulatory value
    • NOTE: Current SAKIGAKE is not applicable for LCM (Expansion of indication).
  – Effective use of real world data (using patient registry initiative)